File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Differential reductions in viral antigens expressed from cccDNAVS integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520

TitleDifferential reductions in viral antigens expressed from cccDNAVS integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520
Authors
Issue Date2016
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S390, abstract no. THU-193 How to Cite?
AbstractBACKGROUND AND AIMS: ARC-520 (ARC), a RNA interference drug, targets cccDNA-derived mRNA in chronic hepatitis B patients (CHB); we previously reported safety and activity of ARC in entecavir (ETV) experienced CHB and preliminary results in treatment-naïve CHB enrolled in a single dose phase 2a study; herein we report full safety and activity against multiple viral antigens and DNA in naïve CHB …
DescriptionPoster Presentations: Viral hepatitis: Hepatitis B & D – experimental: no. THU-193
Persistent Identifierhttp://hdl.handle.net/10722/234185
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorYuen, RMF-
dc.contributor.authorChan, HLY-
dc.contributor.authorLiu, K-
dc.contributor.authorGiven, BD-
dc.contributor.authorSchluep, T-
dc.contributor.authorHamilton, J-
dc.contributor.authorLai, CL-
dc.contributor.authorLocarnini, SA-
dc.contributor.authorLau, JYN-
dc.contributor.authorFerrari, C-
dc.contributor.authorGish, RG-
dc.date.accessioned2016-10-14T06:59:40Z-
dc.date.available2016-10-14T06:59:40Z-
dc.date.issued2016-
dc.identifier.citationThe International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S390, abstract no. THU-193-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/234185-
dc.descriptionPoster Presentations: Viral hepatitis: Hepatitis B & D – experimental: no. THU-193-
dc.description.abstractBACKGROUND AND AIMS: ARC-520 (ARC), a RNA interference drug, targets cccDNA-derived mRNA in chronic hepatitis B patients (CHB); we previously reported safety and activity of ARC in entecavir (ETV) experienced CHB and preliminary results in treatment-naïve CHB enrolled in a single dose phase 2a study; herein we report full safety and activity against multiple viral antigens and DNA in naïve CHB …-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rights© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleDifferential reductions in viral antigens expressed from cccDNAVS integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.doi10.1016/S0168-8278(16)00606-1-
dc.identifier.hkuros267699-
dc.identifier.volume64-
dc.identifier.issue2 suppl.-
dc.identifier.spageS390, abstract no. THU-193-
dc.identifier.epageS390, abstract no. THU-193-
dc.publisher.placeThe Netherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats